The U.S. Food and Drug Administration (FDA) has cleared GE Healthcare's MRI contrast agent, Clariscan, for market in prefilled syringes.
The agent comes in 10-mL, 15-mL, and 20-mL doses. It is macrocyclic and gadolinium-based and has now been approved for use in more than 70 countries around the world, the company said. It was originally cleared by the FDA in November of last year.
